Growing pharma services group Ergomed PLC (LON:ERGO) has appointed Mark Enyedy as its new independent director.
Currently chief executive of Nasdaq-listed ImmunoGen, he was formerly head of corporate development for Shire where he oversaw the acquisitions of NPS Pharmaceuticals and Dyax Corp along with its US$32bn combination with Baxalta.
Ergomed chairman, Dr Miroslav Reljanović, said: "Mark has extensive corporate development experience in the US, UK and globally from his time in senior public company strategic leadership roles.
“Throughout his career he has achieved an outstanding and consistent track record of building new businesses through organic growth, corporate development, and M&A.
“Over the past 20 years, he has been strongly focused on rare disease and oncology and brings to Ergomed exceptional levels of expertise, insight and connections which will support our continuing drive to strengthen our global leadership in these sectors.
“Mark is an outstanding addition to Ergomed, and on behalf of the Board, I am delighted to warmly welcome him to his new position."